Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Lexeo Therapeutics (Nasdaq: LXEO), a clinical stage genetic medicine company focusing on genetically defined cardiovascular diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. R. Nolan Townsend, the company's CEO, will deliver a presentation on Wednesday, January 15, 2025 at 8:15 AM PT in San Francisco, California.

The presentation will be accessible through a live webcast in the News & Events tab of the Investors section on the company's website. A replay option will be made available following the presentation for those unable to attend the live session.

NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases, today announced that R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics, will present at the 43^rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 8:15 AM PT in San Francisco, California.

The event will be webcast live under the News & Events tab in the Investors section of the Company’s website. A replay of the webcast will be available on the website following the presentation.

About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease are treated. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimer’s disease programs.

Media Response:
media@lexeotx.com

Investor Response:
Carlo Tanzi, Ph.D.
ctanzi@kendallir.com

FAQ

When is Lexeo Therapeutics (LXEO) presenting at the 2025 J.P. Morgan Healthcare Conference?

Lexeo Therapeutics will present on Wednesday, January 15, 2025, at 8:15 AM PT in San Francisco, California.

How can investors watch Lexeo Therapeutics' (LXEO) J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation through a live webcast available under the News & Events tab in the Investors section of Lexeo Therapeutics' website. A replay will also be available after the presentation.

What is the focus area of Lexeo Therapeutics (LXEO)?

Lexeo Therapeutics is a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases.

Who will represent Lexeo Therapeutics (LXEO) at the 2025 J.P. Morgan Healthcare Conference?

R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics, will represent the company at the conference.